Jobevne (Bevacizumab-Nwgd) Patent Expiration, LOE Window & CMS Spending

Jobevne (Bevacizumab-Nwgd) by Biocon Biologics: Biologic BLA (PHS Act / Purple Book), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $3,184 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiocon Biologics
FDA Application & PathwayB761175 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (PHS Act / Purple Book)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,184 intro WAC)